600196 复星医药
已收盘 05-06 15:00:00
资讯
新帖
简况
复星医药最新公告:控股子公司获美国FDA药品临床试验批准
证券之星 · 22分钟前
复星医药最新公告:控股子公司获美国FDA药品临床试验批准
《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压
阿斯达克财经 · 05-02
《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压
复星医药今年一季度净利润下滑近四成
新京报网 · 05-02
复星医药今年一季度净利润下滑近四成
野村:复星核心业务增长明确,重申“增持”评级
中金在线 · 05-01
野村:复星核心业务增长明确,重申“增持”评级
复星国际:附属公司复星高科一季度归母净利润同比减少25.4%
界面 · 04-30
复星国际:附属公司复星高科一季度归母净利润同比减少25.4%
复星医药获融资买入0.37亿元,近三日累计买入0.65亿元
金融界 · 04-30
复星医药获融资买入0.37亿元,近三日累计买入0.65亿元
《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%
阿斯达克财经 · 04-30
《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%
复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购
东方网 · 04-29
复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购
复星医药(600196.SH)发布一季度业绩,净利润6.1亿元
智通财经 · 04-29
复星医药(600196.SH)发布一季度业绩,净利润6.1亿元
复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款
智通财经网 · 04-29
复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款
复星医药2024年一季报:实现营收101.57亿元
南方财经网 · 04-29
复星医药2024年一季报:实现营收101.57亿元
图解复星医药一季报:第一季度单季净利润同比减38.22%
证券之星 · 04-29
图解复星医药一季报:第一季度单季净利润同比减38.22%
财报速递:复星医药2024年一季度净利润6.10亿元
同花顺资讯 · 04-29
财报速递:复星医药2024年一季度净利润6.10亿元
复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程
智通财经 · 04-29
复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程
复星医药:一季度净利润6.1亿元 同比下降38.22%
21世纪经济报道 · 04-29
复星医药:一季度净利润6.1亿元 同比下降38.22%
北向资金4月26日净买入复星医药54.67万股 连续3日增持
自选股智能写手 · 04-29
北向资金4月26日净买入复星医药54.67万股 连续3日增持
门海微电子完成C轮融资,融资额亿级人民币,投资方为元禾控股、复星锐正资本等
证券之星 · 04-28
门海微电子完成C轮融资,融资额亿级人民币,投资方为元禾控股、复星锐正资本等
背靠复星,舍得酒业正与百亿目标渐行渐远
观察者网 · 04-26
背靠复星,舍得酒业正与百亿目标渐行渐远
复星医药04月26日主力资金流出236万元 连续3日减仓
自选股智能写手 · 04-26
复星医药04月26日主力资金流出236万元 连续3日减仓
公司概况
公司名称:
上海复星医药(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1998-08-07
主营业务:
上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。
发行价格:
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":24.12,"timestamp":1714978800000,"preClose":23.67,"halted":0,"volume":13530903,"delay":0,"floatShares":2118000000,"shares":2672000000,"eps":0.7518,"marketStatus":"已收盘","marketStatusCode":5,"change":0.45,"latestTime":"05-06 15:00:00","open":23.82,"high":24.2,"low":23.82,"amount":326000000,"amplitude":0.0161,"askPrice":24.13,"askSize":798,"bidPrice":24.12,"bidSize":241,"shortable":0,"etf":0,"ttmEps":0.7518,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715045400000},"adr":0,"adjPreClose":23.67,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":26.04,"lowLimit":21.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2672398711,"pbRate":1.39,"roa":"--","roe":"1.33%","epsLYR":0.89,"committee":-0.127019,"marketValue":64458000000,"floatMarketCap":51098000000,"peRate":32.083001,"changeRate":0.019,"turnoverRate":0.0064,"status":0},"requestUrl":"/m/hq/s/600196/wiki","defaultTab":"wiki","newsList":[{"id":"2433441397","title":"复星医药最新公告:控股子公司获美国FDA药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2433441397","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433441397?lang=zh_cn&edition=full","pubTime":"2024-05-06 17:20","pubTimestamp":1714987207,"startTime":"0","endTime":"0","summary":"复星医药公告,控股子公司复宏汉霖收到美国FDA关于同意HLX22(即抗人表皮生长因子受体-2(HER2)人源化单克隆抗体注射液)联合曲妥珠单抗及化疗一线治疗HER2阳性的晚期胃癌开展临床试验的函。。复宏汉霖拟于条件具备后于美国开展该治疗方案的III期临床试验。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600018970.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432665647","title":"《大行》高盛降复星医药(02196.HK)目标价至20.07元 首季毛利受压","url":"https://stock-news.laohu8.com/highlight/detail?id=2432665647","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432665647?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:22","pubTimestamp":1714634520,"startTime":"0","endTime":"0","summary":"高盛发表报告指出,复星医药(02196.HK) 今年首季收入按年跌6.8%至101亿元人民币,略低于该行预期的107亿元人民币。在剔除疫情产品及收购影响的情况下,现有产品首季增长约5%。集团季内盈利按年跌38.2%至6.1亿元人民币,毛利受压。该行预期,复星医药次季收入增长将改善至4%,下半年将提高至10%。另对其2024至2026年盈利预测下调6.3%、6.5%及2.6%,以反映首季疲弱的业绩。该行对复星医药评级“中性”,目标价由21.53元下调至20.07元。(jl/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-02 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346976/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432609756","title":"复星医药今年一季度净利润下滑近四成","url":"https://stock-news.laohu8.com/highlight/detail?id=2432609756","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2432609756?lang=zh_cn&edition=full","pubTime":"2024-05-02 09:15","pubTimestamp":1714612500,"startTime":"0","endTime":"0","summary":"新京报讯 4月30日,复星医药发布2024年第一季度经营业绩,报告期内实现营收101.57亿元,同比下滑6.56%;归属于上市公司股东的净利润为6.1亿元,同比下滑38.22%。复星医药表示,营收下滑,与2024年阿兹夫定片等新冠相关产品收入同比大幅下降有关。归属于上市公司股东的净利润同比减少,除新冠产品收入同比大幅下滑导致相应利润减少外,还受到Gland Pharma并购Cenexi的摊销及Cenexi的运营亏损等影响。报告期内,复星医药研发费用8.3亿元,多款创新产品获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020916487a57e3b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405020916487a57e3b6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432776577","title":"野村:复星核心业务增长明确,重申“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2432776577","media":"中金在线","top":-1,"share":"https://www.laohu8.com/m/news/2432776577?lang=zh_cn&edition=full","pubTime":"2024-05-01 21:33","pubTimestamp":1714570381,"startTime":"0","endTime":"0","summary":"4月30日,野村东方国际证券发表研究报告指,复星国际有限公司聚焦核心业务战略成效显著,核心业务增长明确,尤以复星旅文增长势头强劲,因此重申复星国际“增持”评级。野村认为消费复苏趋势明确,尤其旅文板块业绩亮眼。野村认为复星国际业务发展向好,给予目标价5.59 港元,潜在上行空间为19.85%,维持“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012140368b6a0215&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012140368b6a0215&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431391512","title":"复星国际:附属公司复星高科一季度归母净利润同比减少25.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431391512","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2431391512?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:20","pubTimestamp":1714468811,"startTime":"0","endTime":"0","summary":"复星国际4月30日在港交所公告,公司附属公司上海复星高科技(集团)有限公司(简称“复星高科”)2024年第一季度营业收入约321.1亿元,同比增长7.3%;归母净利润4308.4万元,同比减少25.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301720117925760f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301720117925760f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431898808","title":"复星医药获融资买入0.37亿元,近三日累计买入0.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431898808","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431898808?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:25","pubTimestamp":1714436713,"startTime":"0","endTime":"0","summary":"4月29日,沪深两融数据显示,复星医药获融资买入额0.37亿元,居两市第345位,当日融资偿还额0.38亿元,净卖出74.48万元。最近三个交易日,25日-29日,复星医药分别获融资买入0.10亿元、0.18亿元、0.37亿元。融券方面,当日融券卖出0.89万股,净买入3.13万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300826548b63f7fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300826548b63f7fe&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431897420","title":"《业绩》复星医药(02196.HK)首季净利润6.1亿人民币 倒退38.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431897420","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431897420?lang=zh_cn&edition=full","pubTime":"2024-04-30 00:23","pubTimestamp":1714407780,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布3月止第一季度报告,按中国会计准则,实现营业收入101.57亿人民币(下同),按年下降6.6%。归属股东净利润6.1亿元,倒退38.2%,主要是今年新冠相关产品销售收入大幅下降,以及并购Cenexi的摊销及运营亏损;每股收益23分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-29 16:25。)过往派息公布日期派息事项派息内容2024/03/26末期业绩普通股息:人民币 0.272023/10/30第三季业绩无派息2023/08/29中期业绩无派息2023/04/28第一季业绩无派息 AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346055/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2431856556","title":"复星医药Q1财报:实现营收101.57亿元,将斥资亿元回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2431856556","media":"东方网","top":-1,"share":"https://www.laohu8.com/m/news/2431856556?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:32","pubTimestamp":1714390366,"startTime":"0","endTime":"0","summary":"财报显示,报告期内,复星医药实现营业收入人民币101.57亿元,归母净利润6.1亿元,重点创新品种收入保持快速增长,收入结构持续优化;报告期内,经营活动产生的现金流量净额9.17亿元,同比增长5.05%。财报显示,今年第一季度,复星医药多款创新产品获批上市,并对上市新品的商业化进程提速。值得注意的是,复星医药也在季报中公布了回购计划。截至4月29日收盘,复星医药报23.71元/股,上涨2.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292011158b61fc4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404292011158b61fc4e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431183146","title":"复星医药(600196.SH)发布一季度业绩,净利润6.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431183146","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431183146?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:57","pubTimestamp":1714388230,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)发布2024年第一季度报告,该公司营业收入为101.57亿元,归属于上市公司股东的净利润6.1亿元,归属于上市公司股东的扣除非经常性损益的净利润6.09亿元,基本每股收益0.23元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114649.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431883946","title":"复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款","url":"https://stock-news.laohu8.com/highlight/detail?id=2431883946","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431883946?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:46","pubTimestamp":1714387592,"startTime":"0","endTime":"0","summary":"复星医药(02196)发布公告,为满足复星凯特生物科技有限公司(以下简称“复星凯特...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_19.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114612.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431833998","title":"复星医药2024年一季报:实现营收101.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431833998","media":"南方财经网","top":-1,"share":"https://www.laohu8.com/m/news/2431833998?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:06","pubTimestamp":1714385160,"startTime":"0","endTime":"0","summary":"南方财经4月29日电,复星医药公布2024年第一季度经营业绩显示,报告期内,复星医药实现营业收入101.57亿元,重点创新品种收入保持快速增长,收入结构持续优化。2024年第一季度,包括自主研发的冻干人用狂犬病疫苗(Vero细胞)等多款创新产品在国内获批上市。此外,2024年4月,注射用曲妥珠单抗(中国境内商品名:汉曲优)获美国FDA批准上市,用于辅助治疗HER2过表达乳腺癌、治疗HER2过表达转移性乳腺癌、以及治疗HER2过表达转移性胃腺癌或胃食管交界腺癌,成为首个在中国、欧盟、美国获批的国产生物类似药。(21世纪经济报道)(文章来源:南方财经网)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291808408b61838b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291808408b61838b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431880817","title":"图解复星医药一季报:第一季度单季净利润同比减38.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431880817","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431880817?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:45","pubTimestamp":1714383957,"startTime":"0","endTime":"0","summary":"证券之星消息,复星医药2024年一季报显示,公司主营收入101.57亿元,同比下降6.56%;归母净利润6.1亿元,同比下降38.22%;扣非净利润6.09亿元,同比下降33.81%;负债率49.42%,投资收益3.36亿元,财务费用2.8亿元,毛利率50.01%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291754218b617272&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291754218b617272&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431884350","title":"财报速递:复星医药2024年一季度净利润6.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431884350","media":"同花顺资讯","top":-1,"share":"https://www.laohu8.com/m/news/2431884350?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:27","pubTimestamp":1714382862,"startTime":"0","endTime":"0","summary":"4月30日,A股上市公司复星医药发布2024年一季度业绩报告。其中,净利润6.10亿元,同比下降38.22%。净利润6.10亿元,同比下降38.22%从营收和利润方面看,公司本报告期实现营业总收入101.57亿元,同比下降6.56%,净利润6.10亿元,同比下降38.22%,基本每股收益为0.23元。综合来看,复星医药总体财务状况尚可,当前总评分为2.08分,在所属的化学制药行业的156家公司中排名靠后。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291727247a5704f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291727247a5704f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431884368","title":"复星医药(02196,600196.SH)2024一季报:创新成果加速兑现,多款新品全面推进商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2431884368","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431884368?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:21","pubTimestamp":1714382486,"startTime":"0","endTime":"0","summary":"4月29日,复星医药公布了2024年第一季度经营业绩。复星医药自主研发的F-i6000全自动化学发光免疫分析仪获批上市,F-i6000为超高速免疫分析仪,具有完全自主知识产权,该产品可接入实验室自动化系统,提供整体解决方案。根据复星医药子公司复宏汉霖的2024年一季报显示,汉曲优实现中国境内销售收入约人民币6.71亿元。同时,复星医药将推进业务聚焦,致力成为全球医疗健康市场一流企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291729328b61530f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291729328b61530f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431843638","title":"复星医药:一季度净利润6.1亿元 同比下降38.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431843638","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2431843638?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:08","pubTimestamp":1714381680,"startTime":"0","endTime":"0","summary":"南方财经4月29日电,复星医药发布一季报,一季度实现净利润6.1亿元,同比下降38.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042917092087be75c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042917092087be75c8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431904968","title":"北向资金4月26日净买入复星医药54.67万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431904968","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431904968?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:30","pubTimestamp":1714354209,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持复星医药54.67万股,连续3日增持。截止当日收盘,沪股通共持有复星医药4901.29万股,占流通股2.31%。沪股通增持金额前五个股分别为招商银行、贵州茅台、兴业银行、药明康德、三一重工。复星医药近5个交易日上涨3.02%,沪股通累计增持149.34万股;近20个交易日上涨1.71%,沪股通累计增持156.98万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290931058b5f9885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290931058b5f9885&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430055126","title":"门海微电子完成C轮融资,融资额亿级人民币,投资方为元禾控股、复星锐正资本等","url":"https://stock-news.laohu8.com/highlight/detail?id=2430055126","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430055126?lang=zh_cn&edition=full","pubTime":"2024-04-28 19:33","pubTimestamp":1714304023,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP于4月27日公布的信息整理,苏州门海微电子科技有限公司完成C轮融资,融资额亿级人民币,参与投资的机构包括元禾控股,复星锐正资本,苏州园区科创基金,南通科技创投。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281935168b5dbefd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404281935168b5dbefd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430274486","title":"背靠复星,舍得酒业正与百亿目标渐行渐远","url":"https://stock-news.laohu8.com/highlight/detail?id=2430274486","media":"观察者网","top":-1,"share":"https://www.laohu8.com/m/news/2430274486?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:08","pubTimestamp":1714136919,"startTime":"0","endTime":"0","summary":"4月25日,舍得酒业披露2024年第一季度报告。报告期内,舍得酒业实现营业收入21.05亿元,同比增长4.13%;归属于上市公司股东的净利润5.5亿元,同比下降3.35%。而事实上,舍得酒业增速快速下降的现象已经持续多年。出人意料的是,在这一行业转折的关键时刻,舍得酒业反而加速推进增产扩能,加大产品研发和区域市场培育。财报数据显示,一季度舍得酒业继续加大科创投入,研发费用2857万元,同比增长72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262109437923f661&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262109437923f661&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430248768","title":"复星医药04月26日主力资金流出236万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2430248768","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430248768?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:17","pubTimestamp":1714115837,"startTime":"0","endTime":"0","summary":"04月26日, 复星医药股价涨1.35%,报收23.19元,成交金额2.60亿元,换手率0.53%,振幅1.84%,量比1.66。复星医药今日主力资金净流出236万元,连续3日净流出,上一交易日主力净流出1741万元,今日环比减少86.44%。该股近5个交易日上涨3.02%,主力资金累计净流出2847万元;近20日主力资金累计净流出1.06亿元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261518538b5607ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261518538b5607ce&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":0.026},{"period":"3month","weight":0.0848},{"period":"6month","weight":-0.1642},{"period":"1year","weight":-0.2427},{"period":"ytd","weight":-0.0543}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267239万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。主要产品为心血管系统疾病治疗领域核心产品、中枢神经系统疾病治疗领域核心产品、血液系统疾病治疗领域核心产品、代谢及消化系统疾病治疗领域核心产品、抗感染疾病治疗领域核心产品、抗肿瘤治疗领域核心产品、原料药和中间体核心产品。根据中华人民共和国工信部中国医药工业信息中心颁布的2018年度中国医药工业百强企业榜单,本集团位列第7;根据IQVIA统计,2019年本集团生产的医院用处方药的销售收入位列全国第10。作为全球最大的抗疟药生产研发制造企业之一,本集团已成为全球基金、联合国儿童基金会、世界卫生组织及非洲各国药品采购中心的抗疟药供应商。本集团持续保持健康高质量发展。由米内研究院主办的“中国医药工业百强系列榜单”,本集团成功入选“2022年度中国化药企业TOP100排行榜”,位列中国化药企业百强榜第6位;根据IQVIA统计,2023年第一季度本集团的医院用处方药销售收入位列全国第12位;根据全球医药智库信息平台InformaPharmaIntelligence发布的《2023年医药研发趋势年度分析》白皮书,本集团再次入选“全球医药企业研发管线规模Top25”。","serverTime":1714988472336,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}